Overview:
Generally, there are three kinds of Neurofibromatosis, i.e., Schwannomatosis, Neurofibromatosis type 1, and Neurofibromatosis type 2. Neurofibromatosis type (NF) 1 is a general type of mono-genic condition of neuro-cutaneous tissue growth which increases secondarily to the mutations of the tumor suppressor gene NF1. It includes an autosomal dominating pattern of inheritance. Patients with NF1 disorder usually have an accelerated pre-disposition to different types of malignant and benign tumors and generate neuro-fibromas along with axillary and inguinal freckling. The Neurofibromatosis 2 (NF2) is a rarely reported disorder than the NF1. General symptoms of NF2 are steady-growing tumors affect the spinal, peripheral nerves, and cranial, and the meninges. The only drug present for treating the NF1 is the Koselugo-selumetinib. Furthermore, the bevacizumab drug is sometimes used as an off-label for treating NF.
The global neurofibromatosis treatment drugs market is expected to manifest a CAGR of 13.40% over the forecast period of 2020-2027 and is estimated to have a market valuation of US$ 8,801.0 million in 2020.
Request Here Sample with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/4188
Drivers
Rising focus of key companies in the market on research and development of novel therapies for treatment of neurofibromatosis. Furthermore, the regulatory authorities-backed clinical studies are expected to propel growth of the global neurofibromatosis treatment drugs market during the forecast period. In October 2019, a bio-pharmacy company, SpringWorks Therapeutics, had initiated the Phase IIb ReNeu clinical trial for evaluating the mirdametinib (formerly PD-0325901), a tiny molecule developed to impede MEK2 and MEK1, in children and adult patients with NF1-related plexiform neurofibromas (NF1-PN). In July 2019, the European Commission had approved this drug of mirdametinib (formerly PD-0325901) developed by SpringWorks Therapeutics for treating the NF1.
Impact of COVID-19 epidemic
The COVID-19 epidemic has substantially impacted the clinical trial in several therapeutic areas. Multiple trials have halted their enrolment and the researchers are facing many issues related to arranging long visits, and carrying out clinical assessments.
On the basis of a survey conducted by an American tech company, Medidata Solutions, Inc., in April, 2020, around 63% of respondents in the survey claimed that they have halted the recruitment of new participants and patients in their current clinical trials and the remaining 43% of survey respondents have re-scheduled their trials.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4188
Owing to the investments made by key companies of the market to boost research and development of novel therapies for treatment of neurofibromatosis, the global neurofibromatosis treatment drugs market is expected to witness a robust growth over the forecast period. In June 2020, a therapeutics developing company, NFlection Therapeutics, Inc., had ended its US$ 20 million Series A funding round with the funding from F-Prime Capital and venBio Partners. The company has disclosed the beginning of its first clinical trial of its leading product, NFX-179 Gel, which is said to be a topical therapy for reduction of NF1.
Key Takeaways of the Global Neurofibromatosis Treatment Drugs Market:
Due to vigorous products in the pipeline and the accelerated approval rate of NF treatment drugs, the global neurofibromatosis treatment drugs market is expected to manifest a CAGR of 13.4% over the forecast period. In April 2020, AstraZeneca Pharmaceuticals received the approval from the U.S. Food and Drugs Administration for its Koselugo (selumetinib) drug for treating the patients affected with pediatric, aging from 2 years and above with NF1.
Increased partnerships between several research organizations has offered an opportunity for major companies to start their clinical trials focused on neurofibromatosis. For e.g., the NF program at Boston Children’s Hospital is among other nine outlets of the national NF clinical trials alliance. It has various research-based projects locally, commenced by clinical investigators. As of now, the organization has 11 active clinical studies focusing on NF.
The only major company contributing in the global neurofibromatosis treatment drugs market is AstraZeneca Plc.
Reasons to Purchase this Report
• Current and future of global Neurofibromatosis Treatment Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Impact Analysis
- Market Opportunities
- Collaborations and Acquisition
- Regulatory Scenario
- Market Dynamics
- Global Neurofibromatosis Treatment Drugs Market, Impact of COVID-19 Pandemic
- During COVID-19 Impact
- Post COVID-19 Impact
- Government Initiatives
- Overall Impact On Healthcare Industry
- Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2016-2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Neurofibromatosis 1 (NF1)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Neurofibromatosis 2 (NF2)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Schwannomatosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Neurofibromatosis 1 (NF1)
- Introduction
- Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017– 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Hospital Pharmacies
- Introduction
- Global Neurofibromatosis Treatment Drugs Market, By Region, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Countries, 2017–2027
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- AstraZeneca Plc.*
- Company Overview
- Disease Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca Plc.*
- Company Profiles
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837